

⑪ Publication number:

**0 133 767**  
**A2**

⑫

## EUROPEAN PATENT APPLICATION

⑲ Application number: 84304992.5

⑤① Int. Cl.<sup>4</sup>: **A 61 K 45/02**

⑳ Date of filing: 23.07.84

③① Priority: 04.08.83 JP 143484/83  
29.08.83 JP 157560/83

④③ Date of publication of application:  
06.03.85 Bulletin 85/10

⑧④ Designated Contracting States:  
BE DE FR GB NL SE

⑦① Applicant: **THE GREEN CROSS CORPORATION**  
15-1, Imabashi-1-chome Higashi-ku Osaka-shi  
Osaka 541(JP)

⑦② Inventor: Noda, Munehiro  
Tacho  
Tenri-Shi(JP)

⑦② Inventor: Fujita, Takaaki  
1-17, Minamishimizucho-3-Cho  
Sakai-Shi(JP)

⑦② Inventor: Morise, Hiroshi  
5-4-1307, Kuzuhahanazonocho  
Hirakata-Shi(JP)

⑦② Inventor: Arimura, Hirofumi  
18-1-401, Uenosaka-2-Chome  
Toyonaka-Shi(JP)

⑦② Inventor: Suyama, Tadakazu  
3-7, Matsuigaoka-4-Chome  
Tanabecho Tsuzuki-Gun Kyoto(JP)

⑦④ Representative: Ellis, John Clifford Holgate et al,  
**MEWBURN ELLIS & CO.** 2/3 Cursitor Street  
London EC4A 1BQ(GB)

⑤④ Gamma interferon composition.

⑤⑦ Gamma interferon obtainable from the human leukocytes, which is unstable even during lyophilization and storage in solid state, can be stabilized by addition of albumin and/or a sugar such as glucose, mannose, galactose, fructose, sucrose, mannitol and xylitol. A stable, lyophilized gamma interferon composition is prepared by lyophilizing its aqueous solution containing the abovementioned stabilizer without lowering its activity.

EP 0 133 767 A2

GAMMA INTERFERON COMPOSITION

1           This invention relates to a stable gamma  
interferon (hereinafter referred to as IFN- $\gamma$ )  
composition.

IFN- $\gamma$  is a glycoprotein having a molecular  
5 weight of about 20,000 to 40,000 which is produced when  
human leukocytes are stimulated with a mitogen such as  
phytohemagglutinin (hereinafter referred to as PHA) or  
concanavarin A (hereinafter referred to as Con-A) used  
as an inducer.

10           IFN- $\gamma$  has a marked immunosuppressive, anti-  
viral and anticellular action; further, it gives a  
synergistic effect to the activity of IFN- $\alpha$  and IFN- $\beta$ ;  
moreover, it has 10 to 100 times as high an anti-  
proliferation effect against tumor cells as that of  
15 IFN- $\alpha$  or IFN- $\beta$ . Accordingly, a great expectation is  
placed on the clinical effect of IFN- $\gamma$  as a medicine.

But IFN- $\gamma$  is unstable to acid conditions (for  
example, pH of about 2) or to heat. It also has a poor  
storage stability in solution. Hence, when IFN- $\gamma$  is to  
20 be used as a medicine, it would be deemed desirable to  
make a lyophilized product of it; but actually, even  
during the lyophilization step it loses its activity.  
Accordingly, it is necessary to stabilize IFN- $\gamma$   
beforehand by some means.

1 Under these circumstances, the inventors,  
after extensive studies, have found out that, when a  
definite amount of a sugar or an albumin is made to  
exist together with IFN- $\gamma$ , the IFN- $\gamma$  is stabilized; no  
5 inactivation takes place during the lyophilization of  
the aqueous solution containing IFN- $\gamma$ ; moreover the  
storage stability of the dry preparation formed by  
lyophilization is improved. This invention has been  
accomplished on the basis of above finding.

10 Thus, this invention relates to a stable IFN- $\gamma$   
composition which comprises IFN- $\gamma$  and a sugar or an  
albumin in an amount sufficient for stabilizing IFN- $\gamma$ .

The IFN- $\gamma$  to be used in this invention is  
usually that which is obtained by purification by chro-  
15 matography using an antigen column or the like of the  
crude IFN- $\gamma$  produced by stimulation of human leukocytes  
with a mitogen such as PHA and Con-A used as an inducer.  
But a wide variety of other IFN- $\gamma$  including those pro-  
duced by E.coli, yeast and the like by virtue of genetic  
20 engineering may also be used irrespective of their  
origin.

The sugars to be used in this invention  
include not only a normal sugar such as monosaccharides  
and disaccharides, but also a sugar alcohol and the mix-  
25 tures thereof. There may be mentioned, as examples of  
monosaccharides, glucose, mannose, galactose and  
fructose; as those of disaccharides, sucrose, maltose

and lactose; and as those of sugar alcohols, mannitol and xylitol. A sugar may be used in admixture with albumin.

The albumin to be used in this invention is preferably of human origin because of the antigenicity problem. Such albumins can be used without further limitation so long as they have been purified for medical use. The purity is preferably such that they contain at least 80% of albumin as determined by electrophoresis analysis. As the methods for obtaining human-origin albumin, there may be mentioned, for example, the ethanol fractionation method (Japanese Patent Publication Nos. 2869/72 and 5297/60) and the method of heating a fraction thereof in the presence of an organic acid (Japanese Patent Publication Nos. 1604/68 and 401321/76). Particularly, albumins which have been subjected to heat treatment (preferably at 60°C for about 10 hours) to effect inactivation of hepatitis virus and the like are preferably used.

The amount of sugar or albumin sufficient for stabilizing IFN- $\gamma$  is in a ratio of at least 5 mg of sugar or at least 3 mg of albumin per  $1 \times 10^2 - 1 \times 10^7$  units of IFN- $\gamma$ , and preferably 10 mg of sugar or 5-10 mg of albumin per  $1 \times 10^4 - 1 \times 10^5$  units of IFN- $\gamma$ . This compounding ratio is applicable to the stabilization of IFN- $\gamma$  in the form of either solid or aqueous solution. In the lyophilization of an aqueous solution of IFN- $\gamma$ , addition of sugar to a concentration of at least 5 mg/ml,

preferably 10 mg/ml of sugar or at least 3 mg/ml, preferably 5 mg/ml of albumin in the solution is sufficient to achieve the stabilization of IFN- $\gamma$ , irrespective of the content of IFN- $\gamma$  in the solution.

- 5        The lyophilization in the presence of sugar or albumin may be performed, for example, as follows. An aqueous solution containing purified IFN- $\gamma$  is adjusted to pH 5 to 9; sugar or albumin is added to the solution in a stabilizing amount mentioned above; the resulting
- 10 aqueous solution is filtered aseptically, dispensed in portions into vials, and then lyophilized in a conventional manner.

The lyophilized preparation of IFN- $\gamma$  thus obtained has preferably a composition approximately corresponding

15 to 10,000 - 500,000 units (preferably 50,000 - 500,000 units) of IFN- $\gamma$ , 5-20 mg (preferably

---

1 10-20 mg) of sugar or 3-20 mg (preferably 5-20 mg) of  
albumin and about 9 - about 18 mg of sodium chloride.

The IFN- $\gamma$  preparation provided by the method  
of this invention is administered orally or paren-  
5 terally. The dose varies depending upon the diseases to  
be treated, administration routes and so forth. When  
used as injections, for example, it is usually made up  
into a solution containing about 1-10% (w/v) of IFN- $\gamma$   
with distilled water or physiological saline solution  
10 for injection, and administered intravenously or intra-  
muscularly at a dose of  $2 \times 10^3$  -  $1 \times 10^4$  units of IFN- $\gamma$   
/kg body weight depending on the symptoms of patients.

In such case albumin would be administered in an amount  
of 0.1-0.4 mg/kg and sugar in an amount of 0.2-0.4 mg/kg.

15 This invention will be described in more  
detail below with reference to Examples and Experimental  
Examples, but it is in no way limited thereto.

#### Examples 1 to 9

20 IFN- $\gamma$  produced in leukocytes with PHA used as  
the stimulant was purified by subjecting it to an affi-  
nity chromatography using Sepharose-monoclonal IFN- $\gamma$   
antibody as column and 2M KSCN solution (pH 8) as eluent  
to give a specific activity of  $10^6$  U/mg or more. The  
25 purified IFN- $\gamma$  was dialyzed against a phosphate-sodium  
chloride buffer solution, pH 7. Then, a series of solu-  
tion groups of various titers was prepared which con-

1    tained the dialyzed IFN- $\gamma$  in concentrations of  $1 \times 10^2$   
units/ml,  $1 \times 10^3$  units/ml,  $1 \times 10^4$  units/ml,  $1 \times 10^5$   
units/ml and  $1 \times 10^6$  units/ml. To each of the solution  
groups, was added glucose (Example 1), mannose (Example  
5    2), galactose (Example 3), fructose (Example 4), sucrose  
(Example 5), maltose (Example 6), lactose (Example 7),  
mannitol (Example 8) or xylitol (Example 9) to a con-  
centration of 10 mg/ml, respectively. The solutions  
were then filtered aseptically, dispensed in 2 ml por-  
10    tions into vials of 10 ml volume, and lyophilized at  
temperatures finally reaching 25°C.

The water content of the resulting lyophilized  
product determined according to "the general method,  
criterion for biological preparations" was found to be  
15    about 0.2% for every specimen. All of the lyophilized  
products dissolved immediately on addition of 2 ml of  
distilled water for injection and gave a clear,  
colorless solution. The amounts of remaining IFN- $\gamma$   
determined with these solutions all showed no difference  
20    from those before lyophilization.

#### Example 10.

Example 1 was repeated, provided that in place  
of glucose to a concentration of 10 mg/ml albumin was  
25    added to a concentration of 5 mg/ml.

The resulting lyophilized product has a water  
content of about 2% and dissolved immediately.

- 1 The property of the solution and the activity of remaining IFN- $\gamma$  therein are same as in Example 1.

Experimental Examp1 1

- 5 A series of experiments was carried out to confirm the stabilizing effect according to this invention. To a solution of purified IFN- $\gamma$  ( $1 \times 10^4$  units/ml; the titer being determined according to the CPE inhibition method in FL-Sindvis Virus system), was added glu-  
10 cose, sucrose, or mannitol to concentrations of 1 mg/ml, 5 mg/ml and 10 mg/ml, respectively, and the resulting solutions were lyophilized. The titer of the product was determined immediately before lyophilization, immediately after lyophilization, and after storage of 6  
15 months at room temperature. The percentage of remaining activity relative to the titer immediately after the addition of sugar was as shown in Table 1.
-



1

Table 1

5

10

15

20

Sugar		Remaining ratio of IFN- $\gamma$ activity (%)		
Kind	Added amount	Immediately before lyophilization	Immediately after lyophilization	6 Months' storage at room temperature
Glucose	1	98	40	19
	5	102	82	76
	10	101	93	89
Sucrose	1	99	46	15
	5	97	86	78
	10	100	96	90
Mannitol	1	100	37	14
	5	101	83	75
	10	99	91	87
None		100	-	32

#### Experimental Example 2

A series of experiments was carried out to confirm the stabilizing effect according to this invention. To a solution of purified IFN- $\gamma$  ( $1 \times 10^4$  units/ml; the titer being determined according to the CPE inhibition method in FL-Sindbis Virus system), was added human

1 serum albumin to various concentrations (0 to 20 mg/ml  
as shown in Fig. 1), and the resulting solutions were  
lyophilized. The titer of the lyophilized product was  
determined immediately after lyophilization (indicated  
5 by symbol O ) and after storage of 6 months at room tem-  
perature (indicated by symbol ● ). The percentage of  
remaining activity relative to the titer immediately  
after the addition of human serum albumin was as shown  
in Fig. 1.


What is claimed is:

1. A stable gamma interferon composition comprising a gamma interferon and an amount sufficient for stabilizing the gamma interferon of a sugar or an albumin.
- 5 2. The stable gamma interferon composition of Claim 1, wherein the sugar is a monosaccharide, a disaccharide or a sugar alcohol.
3. The stable gamma interferon composition of Claim 2, wherein the sugar is glucose, mannose, galac-  
10 tose, fructose, sucrose, maltose, lactose, mannitol or xylitol.
4. The stable gamma interferon composition of any of Claims 1-3, wherein the amount of the sugar is at least 5 mg per  $1 \times 10^2 - 1 \times 10^7$  units of the gamma inter-  
15 feron.
5. The stable gamma interferon composition of Claim 4, wherein the amount of the sugar is 10 mg per  $1 \times 10^4 - 1 \times 10^5$  units of the gamma interferon.
6. The stable gamma interferon composition of any  
20 preceding Claim, which is in the form of a lyophilized solid.
7. The stable gamma interferon composition of any of Claims 1-5, which is in the form of an aqueous solution.
8. The stable gamma interferon composition of any of Claims 1, 6 and 7, wherein the amount of albumin is at least  
25 3 mg per  $1 \times 10^2 - 1 \times 10^7$  units of the gamma interferon.
9. The stable gamma interferon composition of

Claim 8, wherein the amount of albumin is 5-10 mg per  $1 \times 10^4$  -  $1 \times 10^5$  units of the gamma interferon.

10. A process for producing the stable gamma interferon composition of Claim 6, which comprises  
5 lyophilizing the stable gamma interferon composition of Claim 7.

FIG. 1



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☒ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**